Case Study About Acid Phosphatase Levels

Posted on by Vimi

1. Pohlmann R, Krentler C, Schmidt B. Human lysosomal acid phosphatase: cloning, expression and chromosomal assignment. EMBO J 1998;7:2343–50. [PMC free article][PubMed]

2. Moss DW, Raymond FD, Wile DB. Clinical and biological aspects of acid phosphatase. Crit Rev Clin Lab Sci 1995;32:431–67. [PubMed]

3. Sharief FS, Lee H, Lauderman MM, et al. Human prostatic acid phosphatase: cDNA cloning gene mapping and protein sequence homology with lysosomal acid phosphatase. Biochem Biophys Res Commun 1989;160:79–86. [PubMed]

4. Nakanishi M, Yoh K, Uchida K, et al. Improved method for measuring tartrate-resistant acid phosphatase activity in serum. Clin Chem 1998;44:221–5. [PubMed]

5. Lam K-W, Li CY, Yam LT. Comparison of prostatic and nonprostatic acid phosphatase. Ann N Y Acad Sci 1982;390:1–5. [PubMed]

6. Dissing J, Svensmark O. Human red cell acid phosphatase: purification and properties of A, B and C isozymes. Biochim Biophys Acta 1990;1041:232–42. [PubMed]

7. Wo YY, McCormack AL, Shabanowitz J, et al. Sequencing, cloning and expression of human red cell-type acid phosphatase, a cytoplasmic phosphotyrosyl protein phosphatase. J Biol Chem 1992;267:10856–65. [PubMed]

8. Bottini E, Gloria-Bottinin F, Borgiani P, et al. ACP1 and human adaptability. 1. Association with common diseases: a case-control study. Hum Genet 1995;96:629–37. [PubMed]

9. Lord DK, Cross NCP, Bevilacque MA. Sequence, expression and chromosomal localisation of a differentiation-associated protein of the human macrophage. Eur J Biochem 1990;189:287–93. [PubMed]

10. Yam LT. Clinical significance of human acid phosphatases. Am J Med 1974;56:604–16. [PubMed]

11. Hayman AR, Warburton MJ, Pringle JAS. Purification and characterisation of a tartrate-resistant acid phosphatase from human osteoclastomas. Biochem J 1989;261:601–9. [PMC free article][PubMed]

12. Hayman AR, Cox TM. Purple acid phosphatase of the human macrophage and osteoclast. J Biol Chem 1994;269:1294–300. [PubMed]

13. Lam WKW, Lai LC, Yam LT. Tartrate-resistant (band 5) acid phosphatase activity measured by electrophoresis on acrylamide gel. Clin Chem 1978;24:309–12. [PubMed]

14. Nadler HL, Egan TJ. Deficiency of lysosomal acid phosphatase. A new familial metabolic disorder. N Engl J Med 1970;282:302–7. [PubMed]

15. Dattoli M, Wallner K, True L, et al. Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys 1999;45:853–6. [PubMed]

16. Allen SM. An enzyme linked immunosorbent assay (ELISA) for detection of seminal fluid using a monoclonal antibody to prostatic acid phosphatase. J Immunoassay 1995;16:297–308. [PubMed]

17. Minakata K, Asano M. A case study of paternity diagnosis where phenotypes CA and CB of erythrocyte acid phosphatase were found in a putative father and a child, respectively. Nippon Hoigaku Zasshi 1986;40:146–9. [PubMed]

18. Robinson DB, Glew RH. Acid phosphatase in Gaucher's disease. Clin Chem 1980;26:371–82. [PubMed]

19. Giraldo P, Pocovi M, Perez-Calvo J, et al. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics. Haematologica 2000;85:792–9. [PubMed]

20. Wada N, Ussguu S, Ikeda T, et al. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer. Anticancer Res 1999;19:4514–22. [PubMed]

21. Wada N, Fujisaki M, Ishii S, et al. Evaluation of bone metabolic markers in breast cancer with bone metastasis. Breast Cancer 2001;8:131–7. [PubMed]

22. Coen G, Ballanti P, Bonucci E, et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998;13:2294–302. [PubMed]

23. Nadler HL, Egan TJ. Deficiency of lysosomal acid phosphatase. A new familial metabolic disorder. N Engl J Med 1970;282:302–7. [PubMed]

24. Akimoto S, Furuya Y, Akakura K, et al. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase. Int J Urol 1997;6:572–5. [PubMed]

25. Allen SM. An enzyme linked immunosorbent assay (ELISA) for detection of seminal fluid using a monoclonal antibody to prostatic acid phosphatase. J Immunoassay 1995;16:297–308. [PubMed]

26. Bottini E, Lucarelli P, Agostino R, et al. Favism: association with erythrocyte acid phosphatase phenotype. Science 1971;171:409–11. [PubMed]

27. Halleen JM, Alatalo SL, Suominen H, et al. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000;15:1337–45. [PubMed]

28. Janckila AJ, Takahashi K, Sun SZ, et al. Naphthol-ASBI phosphate as a preferred substrate for tartrate-resistant acid phosphatase isoform 5b. J Bone Miner Res 2001;16:788–93. [PubMed]

29. Alatalo SL, Halleen JM, Hentunen TA, et al. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem 2000;46:1751–4. [PubMed]

30. Katagiri M, Ohtawa T, Fukunagaa M, et al. Evaluation of bone loss and serum markers of bone metabolism in patients with hyperparathyroidism. Surg Today 1995;25:598–604. [PubMed]

31. Torress R, de la Piedra C, Rapado A. Clinical usefulness of serum tartrate-resistant acid phosphatase in Paget's disease of bone: correlation with other biochemical markers of bone remodelling. Calcif Tissue Int 1991;49:14–16 [PubMed]

32. de la Piedra Gordo C, Torres Jimenez R. Usefulness of bone remodelling biochemical markers in the diagnosis and follow-up of Paget's bone disease, primary hyperparathyroidism, tumor hypercalcemia and postmenopausal osteoporosis II bone resorption markers. An Med Interna 1991;7:534–8. [PubMed]

33. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982;34:285–90. [PubMed]

34. Kaye M. When is it an osteoclast? J Clin Pathol 1984;37:398–400. [PMC free article][PubMed]

35. Zaidi M, Moonga B, Moss DW, et al. Inhibition of osteoclastic acid phosphatase abolishes bone resorption. Biochem Biophys Res Commun 1989;159:68–71. [PubMed]

36. Hayman AR, Jones SJ, Boyde A, et al. Mice lacking tartrate-resistant acid phosphatase (ACP5) have disrupted endochondral ossification and mild osteopetrosis. Development 1997;122:3151–62. [PubMed]

37. Cheung CK, Panesar NS, Haines C, et al. Immunoassay of a tartrate resistant acid phosphatase in serum. Clin Chem 1995;41:679–86. [PubMed]

38. Halleen JM, Karp M, Viloma S, et al. Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterisation of six monoclonal antibodies. J Bone Miner Res 1999;14:464–9. [PubMed]

39. Chamberlain P, Compston J, Cox TM, et al. Generation and characterisation of monoclonal antibodies to human type-5 tartrate-resistant acid phosphatase: development of a specific immunoassay of the isoenzyme in serum. Clin Chem 1995;41:1495–9. [PubMed]

40. Lau KHW, Onishi T, Wergedal JE, et al. Characterisation and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin Chem 1987;33:458–62. [PubMed]

41. Rico H, Villa LF. Serum tartrate resistant acid phosphatase (TRAP) as a biochemical marker of bone remodelling. Calcif Tissue Int 1993;52:149–50. [PubMed]

42. Atkins GJ, Haynes DR, Geary SM, et al. Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. Bone 2000;26:653–6. [PubMed]

43. Azuma Y, Kaji K, Katogi R, et al. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000;275:4858–64. [PubMed]

44. Manolagas SC. The role of IL-6 type cytokines and their receptors in bone. Ann N Y Acad Sci 1998;840:194–204.. [PubMed]

45. Takeshita S, Kaji K, Kudo A. Identification and characterisation of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 2000;15:1477–88. [PubMed]

46. Salo J, Lehenkari P, Mulari M, et al. Removal of osteoclast bone resorption products by transcytosis. Science 1997;276:270–3. [PubMed]

47. Nesbitt SA, Horton MA. Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 1997;276:266. [PubMed]

48. Biskobing DM, Fan D. Acid pH increases carbonic-anhydrase II and calcitonin receptor mRNA expression in mature OC. Calcif Tissue Int 2000;67:178–83. [PubMed]

49. Marshall K, Nash K, Haussman G, et al. Recombinant human and mouse purple acid phosphatases: expression and characterisation. Arch Biochem Biophys 1997;345:230–6. [PubMed]

50. Sundquist K, Lakkakorpi P, Wallmark B, et al. Inhibition of osteoclast proton transport by bafilomycin A1 abolishes bone resorption. Biochem Biophys Res Commun 1990;168:309–13. [PubMed]

51. Li YP, Chen W, Liang Y, et al. Atp6I-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 1999;23:4447–51. [PubMed]

52. Dodds RA, James JE, Rieman D, et al. Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption. J Bone Miner Res 2001;16:478–86. [PubMed]

53. Kobayashi Y, Hashimoto F, Miyamoto H, et al. Forced inducted osteoclasts apoptosis in vivo accompanied by elevation in transforming growth factor beta and osteoprotegrin expression. J Bone Miner Res 2000;15:1924–1934. [PubMed]

54. Ljusberg J, Ek-Rylander B, Andersson G. Tartrate-resistant purple acid phosphatase is synthesised as a latent proenzyme and activated by cysteine proteinases. Biochem J 1999;343:63–9. [PMC free article][PubMed]

55. Reinholt FP, Mengarelli-Widholm S, Ek-Rylander B, et al.. Ultrastructural localisation of tartrate-resistant acid ATPase in bone. J Bone Miner Res 1990;5:1055–61. [PubMed]

56. Halleen JM, Jaija H, Stepan JJ, et al. Studies on the protein tyrosine phosphatase activity of tartrate-resistant acid phosphatase. Arch Biochem Biophys 1998;352:97–102. [PubMed]

57. Ek-Rylander B, Flores M, Wendal M, et al. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. J Biol Chem 1994;269:14853–6. [PubMed]

58. Asou Y, Rittling SR, Yoshitake H, et al.. Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone. Endocrinology 2001;142:1325–32. [PubMed]

59. Flores ME, Norgard M, Heinegard D. RGD-directed attachment of isolated rat osteoclasts to osteopontin, bone sialoprotein, and fibronectin. Exp Cell Res 1992;201:526–30. [PubMed]

60. Halleen JM, Saisanen S, Salo J, et al. Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 1999;274:22907–10. [PubMed]

61. Fukushima O, Bekker PJ, Gay CV. Ultrastructural localisation of tartrate-resistant acid phosphatase (purple acid phosphatase) activity in chicken cartilage and bone. Am J Anat 1991;191:228–36. [PubMed]

62. Kawabe H, Sugiura Y, Terauchi M, et al


Anas K Gremida, MD Resident Physician, Combined Internal Medicine-Pediatrics Program, St Louis University School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Thomas M Wheeler, MD Chairman, Department of Pathology and Immunology, WL Moody, Jr, Professor of Pathology, Professor of Urology, Baylor College of Medicine

Thomas M Wheeler, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American Medical Association, American Society for Clinical Pathology, American Society of Cytopathology, American Thyroid Association, American Urological Association, College of American Pathologists, United States and Canadian Academy of Pathology, International Society of Urological Pathology, Harris County Medical Society

Disclosure: Received stock from PathXL for medical advisory board. for: PathXL, Inc.


Judy Lin, MD

Disclosure: Nothing to disclose.

Categories: 1

0 Replies to “Case Study About Acid Phosphatase Levels”

Leave a comment

L'indirizzo email non verrĂ  pubblicato. I campi obbligatori sono contrassegnati *